Across TCGA pan-cancer cohorts, CEACAM16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEACAM16 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher CEACAM16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEACAM16 expression acts as an unfavorable survival marker.

KICH, KIRP, and UCEC are the cancer types where CEACAM16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
KIRP	OS	Median	All	0.135	0.703	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CEACAM16 tumor-vs-normal RNA expression · all CEACAM16 data types